Adma Biologics (ADMA) Non Operating Income (2011 - 2026)
Adma Biologics' (ADMA) quarterly Non Operating Income came in at -$1.2 million in Q4 2025, up 67.98% YoY from -$688186.0 in Q4 2024, and up 66.94% on a QoQ basis from -$3.5 million in Q3 2025.
Adma Biologics (ADMA) Non Operating Income (2011 - 2026) Analysis & Trends
Adma Biologics (ADMA) has 13 years of Non Operating Income data on file, last reported at -$1.2 million in Q4 2025.
- Quarterly Non Operating Income rose 67.98% year-over-year to -$1.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$8.8 million (up 33.79% YoY) and the FY2025 annual result came in at -$8.8 million, up 33.78% from the prior year.
- Non Operating Income rose to -$1.2 million in Q4 2025, from -$3.5 million in the prior quarter.
- In the past five years, Non Operating Income ranged from a high of -$1.2 million in Q4 2025 to a low of -$31.9 million in Q4 2023.
- A 5-year average of -$5.3 million and a median of -$3.5 million in 2021 frame the typical range for Non Operating Income.
- Annual changes were most pronounced in 2023 — Non Operating Income tumbled 416.39% — and 2024, when it surged 88.68%.
- Tracing ADMA's Non Operating Income over 5 years: stood at -$3.5 million in 2021, then plunged by 78.5% to -$6.2 million in 2022, then plunged by 416.39% to -$31.9 million in 2023, then surged by 88.68% to -$3.6 million in 2024, then soared by 67.98% to -$1.2 million in 2025.
- The last three Non Operating Income figures came in at -$1.2 million (Q4 2025), -$3.5 million (Q3 2025), and -$2.7 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -139.24 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 12.40 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -51.63 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -53.64 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Adma Biologics | 2.13 Bn | 2.00 Bn | 86.28 Mn | -2.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -2.21 Mn |
| Dec 31, 2025 | -1.16 Mn |
| Sep 30, 2025 | -3.50 Mn |
| Jun 30, 2025 | -2.70 Mn |
| Mar 31, 2025 | -1.43 Mn |
| Dec 31, 2024 | -3.61 Mn |
| Sep 30, 2024 | -2.89 Mn |
| Jun 30, 2024 | -3.35 Mn |
| Mar 31, 2024 | -3.42 Mn |
| Dec 31, 2023 | -31.88 Mn |
| Sep 30, 2023 | -6.12 Mn |
| Jun 30, 2023 | -5.90 Mn |
| Mar 31, 2023 | -5.98 Mn |
| Dec 31, 2022 | -6.17 Mn |
| Sep 30, 2022 | -5.58 Mn |
| Jun 30, 2022 | -4.59 Mn |
| Mar 31, 2022 | -3.52 Mn |
| Dec 31, 2021 | -3.46 Mn |
| Sep 30, 2021 | -3.28 Mn |
| Jun 30, 2021 | -3.32 Mn |